Andrew Witty, chief executive officer at GlaxoSmithKline (NYSE: GSK) still wants to buy Human Genome Sciences, but he doesn’t want AstraZeneca.

Asked at GSK’s annual meeting on Thursday if GSK had interest in AstraZeneca (NYSE: AZN), Witty said no, according to a report from Reuters. He said such a deal would be “very distracting.”

However, Witty reiterated that GSK still wants Human Genome Services (Nasdaq: HGSI).

GSK, which operates its U.S. headquarters in RTP, has offered $2.6 billion for HGS. HGS has rejected the offer.

“We think we can deliver an extraordinary return to (GSK) shareholders through this acquisition,” Witty said.

Read more details here.